Filing Details
Silexion Therapeutics Corp (NASDAQ:SLXN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:SLXN
Silexion Therapeutics Corp (SLXN) Files Quarterly Report for Q0
Silexion Therapeutics Corp (NASDAQ:SLXN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
At publication ·
What changed
Silexion Therapeutics Corp (NASDAQ:SLXN) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Silexion Therapeutics Corp filed its Q0 2026 quarterly report (Form 10-Q) on August 14, 2026 with the SEC.
- The company's stock trades at $0.42 per share with a market capitalization of $1.7 million.
- The quarterly report contains unaudited financial statements and management commentary on business performance, though specific revenue figures were not disclosed in this summary.
Market Context
Silexion Therapeutics Corp's stock currently trades at $0.42 with a market capitalization of $1.7M.
The 10-Q provides Silexion Therapeutics Corp's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Silexion Therapeutics Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SLXN Stock Page
Frequently Asked Questions
Where can I read SLXN's SEC filings?
Browse all filings on our SLXN SEC filings page.
What types of SEC filings does Silexion Therapeutics Corp file?
Public companies like Silexion Therapeutics Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.